Comparison between Fractal Industries IPO and Goldline Pharmaceutical IPO.
Fractal Industries IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Goldline Pharmaceutical IPO is a SME Bookbuilding proposed to list at BSE SME.
| Fractal Industries IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Finaax Capital Advisors Pvt.Ltd. | Cumulative Capital Pvt.Ltd. |
| Registrar | Kfin Technologies Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Shreni Shares Ltd. | Nirman Share Brokers Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | Anchor Investor |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Fractal Industries IPO is up to ₹46.54 Cr whereas the issue size of the Goldline Pharmaceutical IPO is up to ₹11.02 Cr. The final issue price of Fractal Industries IPO is ₹216.00 per share and of Goldline Pharmaceutical IPO is ₹43.00 per share.
| Fractal Industries IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹205.00 per share | ₹41.00 per share |
| Issue Price (Upper) | ₹216.00 per share | ₹43.00 per share |
| Issue Price (Final) | ₹216.00 per share | ₹43.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 600 shares | 3000 shares |
| Fresh Issue Size | 21,54,600 shares | 25,62,000 shares |
| Fresh Issue Size (Amount) | up to ₹46.54 Cr | up to ₹11.02 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 21,54,600 shares | 25,62,000 shares |
| Issue Size Total (Amount) | up to ₹46.54 Cr | up to ₹11.02 Cr |
Fractal Industries IPO opens on Feb 16, 2026, while Goldline Pharmaceutical IPO opens on May 12, 2026. The closing date of Fractal Industries IPO and Goldline Pharmaceutical IPO is Feb 18, 2026, and May 14, 2026, respectively.
| Fractal Industries IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Anchor Bid Date | Feb 13, 2026 | May 11, 2026 |
| Issue Open | Feb 16, 2026 | May 12, 2026 |
| Issue Close | Feb 18, 2026 | May 14, 2026 |
| Basis Of Allotment (Tentative) | Feb 20, 2026 | May 15, 2026 |
| Initiation of Refunds (Tentative) | Feb 23, 2026 | May 18, 2026 |
| Credit of Share (Tentative) | Feb 23, 2026 | May 18, 2026 |
| Listing date (Tentative) | Feb 24, 2026 | May 19, 2026 |
| Anchor Lockin End date 1 | Mar 22, 2026 | Jun 14, 2026 |
| Anchor Lockin End date 2 | May 21, 2026 | Aug 13, 2026 |
Fractal Industries IPO P/E ratio is 15.99, as compared to Goldline Pharmaceutical IPO P/E ratio of 10.47.
| Fractal Industries IPO | Goldline Pharmaceutical IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 97.15 | 79.70 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 69.07 | 57.29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 15.99 | 10.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹169.54 Cr. | ₹41.28 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 63.20 | 35.83 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 25.07 | 38.45 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.76 | 1.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹13.51 | ₹4.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 48.02 | 27.37 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Fractal Industries IPO Retail Individual Investors (RII) are offered 7,54,800 shares while in Goldline Pharmaceutical IPO retail investors are offered 7,54,800 shares. Qualified Institutional Buyers (QIB) are offered 4,30,800 shares in Fractal Industries IPO and 5,40,000 shares in Goldline Pharmaceutical IPO.
| Fractal Industries IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Anchor Investor Reservation | 6,45,000 shares | 7,32,000 shares |
| Market Maker Reservation | 1,14,000 shares | 1,38,000 shares |
| QIB | 4,30,800 shares | 5,40,000 shares |
| NII | 3,24,000 shares | 3,90,000 shares |
| RII | 7,54,800 shares | 9,00,000 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 21,54,600 shares | 25,62,000 shares |
Fractal Industries IPO subscribed 3.81x in total, whereas Goldline Pharmaceutical IPO subscribed 600.53x.
| Fractal Industries IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| QIB (times) | 5.95x | 180.22x |
| NII (times) | 7.91x | 1,662.04x |
| Big NII (times) | 9.45x | 2,010.60x |
| Small NII (times) | 4.85x | 980.75x |
| RII (times) | 4.09x | 881.15x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 3.81x | 600.53x |
